74 related articles for article (PubMed ID: 17459472)
1. Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia.
Schimmel KJ; Nijmeijer BA; van Schie ML; Falkenburg JH; Guchelaar HJ
Leuk Res; 2007 Nov; 31(11):1545-51. PubMed ID: 17459472
[TBL] [Abstract][Full Text] [Related]
2. Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity.
Ford H; Driscoll JS; Hao Z; Dobyns KA; Rommel ME; Stowe E; Anderson JO; Plowman J; Waud WR; Johns DG
Biochem Pharmacol; 1995 Jan; 49(2):173-80. PubMed ID: 7840794
[TBL] [Abstract][Full Text] [Related]
3. Studies on the antitumor activity and biochemical actions of cyclopentenyl cytosine against human colon carcinoma HT-29 in vitro and in vivo.
Gharehbaghi K; Zhen W; Fritzer-Szekeres M; Szekeres T; Jayaram HN
Life Sci; 1999; 64(2):103-12. PubMed ID: 10069488
[TBL] [Abstract][Full Text] [Related]
4. Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of 1-beta-D-arabinofuranosyl cytosine in a human T-lymphoblastic cell line.
Verschuur AC; Van Gennip AH; Leen R; Voûte PA; Brinkman J; Van Kuilenburg AB
Int J Cancer; 2002 Apr; 98(4):616-23. PubMed ID: 11920624
[TBL] [Abstract][Full Text] [Related]
5. Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts.
Ford H; Cooney DA; Ahluwalia GS; Hao Z; Rommel ME; Hicks L; Dobyns KA; Tomaszewski JE; Johns DG
Cancer Res; 1991 Jul; 51(14):3733-40. PubMed ID: 1712247
[TBL] [Abstract][Full Text] [Related]
6. Cyclopentenyl cytosine (CPEC): an overview of its in vitro and in vivo activity.
Schimmel KJ; Gelderblom H; Guchelaar HJ
Curr Cancer Drug Targets; 2007 Aug; 7(5):504-9. PubMed ID: 17691910
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition of cytidine triphosphate synthetase activity by cyclopentenyl cytosine in paediatric acute lymphocytic leukaemia.
Verschuur AC; Van Gennip AH; Leen R; Meinsma R; Voute PA; van Kuilenburg AB
Br J Haematol; 2000 Jul; 110(1):161-9. PubMed ID: 10930994
[TBL] [Abstract][Full Text] [Related]
8. Resistance to cyclopentenylcytosine in murine leukemia L1210 cells.
Zhang H; Cooney DA; Zhang MH; Ahluwalia G; Ford H; Johns DG
Cancer Res; 1993 Dec; 53(23):5714-20. PubMed ID: 7694793
[TBL] [Abstract][Full Text] [Related]
9. Cyclopentenyl cytosine induces apoptosis and increases cytarabine-induced apoptosis in a T-lymphoblastic leukemic cell-line.
Verschuur AC; Brinkman J; Van Gennip AH; Leen R; Vet RJ; Evers LM; Voûte PA; Van Kuilenburg AB
Leuk Res; 2001 Oct; 25(10):891-900. PubMed ID: 11532523
[TBL] [Abstract][Full Text] [Related]
10. Absence of cardiotoxicity of the experimental cytotoxic drug cyclopentenyl cytosine (CPEC) in rats.
Schimmel K; Bennink R; de Bruin K; Leen R; Sand K; van den Hoff M; van Kuilenburg A; Vanderheyden JL; Steinmetz N; Pfaffendorf M; Verschuur A; Guchelaar HJ
Arch Toxicol; 2005 May; 79(5):268-76. PubMed ID: 15902424
[TBL] [Abstract][Full Text] [Related]
11. In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors.
Viola JJ; Agbaria R; Walbridge S; Oshiro EM; Johns DG; Kelley JA; Oldfield EH; Ram Z
Cancer Res; 1995 Mar; 55(6):1306-9. PubMed ID: 7882327
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells.
Agbaria R; Kelley JA; Jackman J; Viola JJ; Ram Z; Oldfield E; Johns DG
Oncol Res; 1997; 9(3):111-8. PubMed ID: 9220496
[TBL] [Abstract][Full Text] [Related]
13. Will cyclopentenyl cytosine (CPEC) ever have a future in the clinic?
van Bree C; van Kuilenburg AB
Leuk Res; 2008 Feb; 32(2):201-2. PubMed ID: 17681375
[No Abstract] [Full Text] [Related]
14. Cyclopentenyl cytosine and neuroblastoma SK-N-BE(2)-C cell line cells.
Slingerland RJ; Van Gennip AH; Bodlaender JM; Voûte PA; Van Kuilenburg AB
Eur J Cancer; 1995; 31A(4):627-31. PubMed ID: 7576983
[TBL] [Abstract][Full Text] [Related]
15. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
16. CPEC induces erythroid differentiation of human myeloid leukemia K562 cells through CTP depletion and p38 MAP kinase.
Huang M; Wang Y; Collins M; Graves LM
Leukemia; 2004 Nov; 18(11):1857-63. PubMed ID: 15385935
[TBL] [Abstract][Full Text] [Related]
17. IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples.
Piloto O; Nguyen B; Huso D; Kim KT; Li Y; Witte L; Hicklin DJ; Brown P; Small D
Cancer Res; 2006 May; 66(9):4843-51. PubMed ID: 16651440
[TBL] [Abstract][Full Text] [Related]
18. Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography.
Agbaria R; Ford H; Kelley JA; Xie F; Politi P; Grem JL; Cooney DA; Marquez VE; Allegra CJ; Johns DG
Anal Biochem; 1993 Aug; 213(1):90-6. PubMed ID: 8238887
[TBL] [Abstract][Full Text] [Related]
19. Cyclopentenyl cytosine primes SK-N-BE(2)c neuroblastoma cells for cytarabine toxicity.
Bierau J; Van Gennip AH; Leen R; Helleman J; Caron HN; Van Kuilenburg AB
Int J Cancer; 2003 Jan; 103(3):387-92. PubMed ID: 12471622
[TBL] [Abstract][Full Text] [Related]
20. Cyclopentenyl cytosine inhibits cytidine triphosphate synthetase in paediatric acute non-lymphocytic leukaemia: a promising target for chemotherapy.
Verschuur AC; Van Gennip AH; Leen R; Muller EJ; Elzinga L; Voûte PA; Van Kuilenburg AB
Eur J Cancer; 2000 Mar; 36(5):627-35. PubMed ID: 10738128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]